RaQualia Pharma Inc. (4579) Stock Price

Rakuoria Drug Discovery is a drug discovery venture company with a single business segment. The company consists of Rakuoria Drug Discovery Inc. and its consolidated subsidiaries, Temric Inc. and Phimex Inc. It primarily aims to develop new pharmaceuticals in the medical field and generates revenue by licensing out intellectual property rights for its proprietary drug compounds to pharmaceutical companies.

In pharmaceutical research and development, the company focuses on exploratory research, preclinical testing, and early-stage clinical trials. Since late-stage trials such as Phase III clinical trials require substantial investment, the company conducts research through early Phase II clinical trials in-house and then out-licenses its drug compounds to pharmaceutical companies.

Rakuoria Drug Discovery has conducted research and development on small-molecule compounds, and in recent years has also advanced its research and development of biopharmaceuticals such as antibody drugs and vaccines. Leveraging its existing technological capabilities, the company is also exploring expansion into new modalities beyond small-molecule compounds.

The company's revenue consists of upfront contract payments, milestone payments, royalty income, and research collaboration fees. These are generated based on the out-licensing of drug compounds and the results of collaborative research.

Rakuoria Drug Discovery has focused its research and development on gastrointestinal and pain-related diseases, but currently is also prioritizing areas with high medical needs, such as cancer and neurological diseases. The company is expanding its research and development scope through collaboration with Nagoya University and acquisitions of subsidiaries.

The company operates three programs: a pre-out-licensing program, an out-licensed program, and a collaborative research program. Through these programs, the company advances research and development of drug compounds and aims for out-licensing to pharmaceutical companies. In collaborative research, the company cooperates with other organizations to expand drug discovery possibilities.

Rakuoria Drug Discovery is a drug discovery venture company that aims to develop new pharmaceuticals in the healthcare field by leveraging cutting-edge scientific technology. The company operates a business model in which it out-licenses drug compounds developed in-house to pharmaceutical companies, generating revenue through upfront payments and royalties.

The company's growth strategy focuses on establishing an integrated drug discovery business model that spans from basic research through early-stage development to out-licensing. By creating innovative drug compounds through industry-academia-government partnerships and building trust-based relationships with business partners, the company aims to achieve reliable business results.

Rakuoria Drug Discovery is strengthening its research and development project portfolio to advance pharmaceutical research and achieve sustainable growth. The company prioritizes pain-related and gastrointestinal diseases, while also focusing on high-demand medical areas such as cancer and neurological diseases.

The company deploys out-licensing and alliance management strategies, leveraging its research and development portfolio to maximize revenue. It is strengthening cooperation with out-licensing partners to achieve early revenue generation and secure long-term revenue streams.

As part of its research and development strategy, the company is advancing work on novel modalities derived from small-molecule compounds. Through collaborations with Nagoya University and Gifu Pharmaceutical University, the company is strengthening drug discovery research based on cutting-edge research outcomes and enhancing its research and development portfolio.

Rakuoria Drug Discovery is also focusing on strengthening its financial foundation and expanding human capital. Through diversified fundraising and cost control, the company is reinforcing its financial base while securing and developing highly specialized talent. This approach aims to maintain and advance the company's growth capacity.